Replies to post #792 on Israel-Medical-Healthcare

[genisi]

Can-Fite announced today that it will receive a $500,000 milestone payment from Seikagaku Corporation after submitting
the CF101 phase IIb results for the RA indication.
Guess the Japanese don't think the placebo effect in that trial is critical.